Schlesinger N. Diagnosing and treating gout: a review to aid primary care physicians. „Postgrad Med”. 122 (2), s. 157–61, Marzec 2010. DOI: 10.3810/pgm.2010.03.2133. PMID: 20203467.
Terkeltaub R. Update on gout: new therapeutic strategies and options. „Nat Rev Rheumatol”. 6 (1), s. 30–8, styczeń 2010. DOI: 10.1038/nrrheum.2009.236. PMID: 20046204.
Tausche AK, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U. Gout--current diagnosis and treatment. „Dtsch Arztebl Int”. 106 (34–35), s. 549–55, sierpień 2009. DOI: 10.3238/arztebl.2009.0549. PMID: 19795010. PMCID: PMC2754667.
Vitart V, Rudan I, Hayward C. i wsp.. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. „Nat. Genet.”. 40 (4), s. 437–42, kwiecień 2008. DOI: 10.1038/ng.106. PMID: 18327257.
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. „N. Engl. J. Med.”. 350 (11), s. 1093–103, marzec 2004. DOI: 10.1056/NEJMoa035700. PMID: 15014182.
Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. „Curr Opin Rheumatol”. 22 (2), s. 165–72, marzec 2010. DOI: 10.1097/BOR.0b013e328335ef38. PMID: 20035225.
TR Merriman, N Dalbeth. The genetic basis of hyperuricaemia and gout.. „Joint, bone, spine : revue du rhumatisme”. 78 (1), s. 35–40, 2011 Jan. DOI: 10.1016/j.jbspin.2010.02.027. PMID: 20472486.
Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. „Nat Rev Rheumatol”, Wrzesień 2012. DOI: 10.1038/nrrheum.2012.144. PMID: 22945592.
Loghman-Adham M. Renal effects of environmental and occupational lead exposure. „Environ. Health Perspect.”. 105 (9), s. 928–38, wrzesień 1997. Brogan & Partners. DOI: 10.2307/3433873. PMID: 9300927. PMCID: PMC1470371. JSTOR: 3433873.
Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.. „BMJ”. 344, s. d8190, 2012. DOI: 10.1136/bmj.d8190. PMID: 22240117. PMCID: PMC3257215.
Jordan DR, Belliveau MJ, Brownstein S, McEachren T, Kyrollos M. Medial canthal tophus. „Ophthal Plast Reconstr Surg”. 24 (5), s. 403–4, 2008. DOI: 10.1097/IOP.0b013e3181837a31. PMID: 18806664.
Sano K, Kohakura Y, Kimura K, Ozeki S. Atypical Triggering at the Wrist due to Intratendinous Infiltration of Tophaceous Gout. „Hand (N Y)”. 4 (1), s. 78–80, marzec 2009. DOI: 10.1007/s11552-008-9120-4. PMID: 18780009. PMCID: PMC2654956.
Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. „Arthritis Rheum.”. 57 (5), s. 816–21, Czerwiec 2007. DOI: 10.1002/art.22762. PMID: 17530681.
Zhang W, Doherty M, Bardin T. i wsp.. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). „Ann. Rheum. Dis.”. 65 (10), s. 1312–24, Październik 2006. DOI: 10.1136/ard.2006.055269. PMID: 16707532. PMCID: PMC1798308.
Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. „Annals of Emergency Medicine”. 49 (5), s. 670–7, 2007. DOI: 10.1016/j.annemergmed.2006.11.014. PMID: 17276548.
JS Sundy, Baraf, HS, Yood, RA, Edwards, NL, Gutierrez-Urena, SR, Treadwell, EL, Vázquez-Mellado, J, White, WB, Lipsky, PE, Horowitz, Z, Huang, W, Maroli, AN, Waltrip RW, 2nd, Hamburger, SA, Becker, MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.. „JAMA: the Journal of the American Medical Association”. 306 (7), s. 711–20, 17.08.2011. DOI: 10.1001/jama.2011.1169. PMID: 21846852.
NaomiN.SchlesingerNaomiN. i inni, Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions, „Annals of the Rheumatic Diseases”, 71 (11), 2012, s. 1839–1848, DOI: 10.1136/annrheumdis-2011-200908, ISSN0003-4967.
Loghman-Adham M. Renal effects of environmental and occupational lead exposure. „Environ. Health Perspect.”. 105 (9), s. 928–38, wrzesień 1997. Brogan & Partners. DOI: 10.2307/3433873. PMID: 9300927. PMCID: PMC1470371. JSTOR: 3433873.
Schlesinger N. Diagnosing and treating gout: a review to aid primary care physicians. „Postgrad Med”. 122 (2), s. 157–61, Marzec 2010. DOI: 10.3810/pgm.2010.03.2133. PMID: 20203467.
Terkeltaub R. Update on gout: new therapeutic strategies and options. „Nat Rev Rheumatol”. 6 (1), s. 30–8, styczeń 2010. DOI: 10.1038/nrrheum.2009.236. PMID: 20046204.
Tausche AK, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U. Gout--current diagnosis and treatment. „Dtsch Arztebl Int”. 106 (34–35), s. 549–55, sierpień 2009. DOI: 10.3238/arztebl.2009.0549. PMID: 19795010. PMCID: PMC2754667.
Vitart V, Rudan I, Hayward C. i wsp.. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. „Nat. Genet.”. 40 (4), s. 437–42, kwiecień 2008. DOI: 10.1038/ng.106. PMID: 18327257.
AL Weaver. Epidemiology of gout. „Cleveland Clinic journal of medicine”. 75 Suplement 5, s. S9–12, lipiec 2008. PMID: 18819329.
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. „N. Engl. J. Med.”. 350 (11), s. 1093–103, marzec 2004. DOI: 10.1056/NEJMoa035700. PMID: 15014182.
Weaver AL. Epidemiology of gout. „Cleve Clin J Med”. 75 Suplement 5, s. S9–12, lipiec 2008. PMID: 18819329.
Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. „Am. J. Clin. Nutr.”. 87 (5), s. 1480–7, maj 2008. PMID: 18469274.
Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. „Curr Opin Rheumatol”. 22 (2), s. 165–72, marzec 2010. DOI: 10.1097/BOR.0b013e328335ef38. PMID: 20035225.
TR Merriman, N Dalbeth. The genetic basis of hyperuricaemia and gout.. „Joint, bone, spine : revue du rhumatisme”. 78 (1), s. 35–40, 2011 Jan. DOI: 10.1016/j.jbspin.2010.02.027. PMID: 20472486.
Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. „Nat Rev Rheumatol”, Wrzesień 2012. DOI: 10.1038/nrrheum.2012.144. PMID: 22945592.
Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. „Drugs”. 65 (18), s. 2593–611, 2005. PMID: 16392875.
Loghman-Adham M. Renal effects of environmental and occupational lead exposure. „Environ. Health Perspect.”. 105 (9), s. 928–38, wrzesień 1997. Brogan & Partners. DOI: 10.2307/3433873. PMID: 9300927. PMCID: PMC1470371. JSTOR: 3433873.
Laubscher T, Dumont Z, Regier L, Jensen B. Taking the stress out of managing gout. „Can Fam Physician”. 55 (12), s. 1209–12, Grudzień 2009. PMID: 20008601. PMCID: PMC2793228.
Virsaladze DK, Tetradze LO, Dzhavashvili LV, Esaliia NG, Tananashvili DE. Levels of uric acid in serum in patients with metabolic syndrome. „Georgian Med News”, s. 35–7, Maj 2007. PMID: 17595458. (ros.).
Moyer RA, John DS. Acute gout precipitated by total parenteral nutrition. „The Journal of rheumatology”. 30 (4), s. 849–50, Kwiecień 2003. PMID: 12672211.
Halabe A, Sperling O. Uric acid nephrolithiasis. „Mineral and electrolyte metabolism”. 20 (6), s. 424–31, 1994. PMID: 7783706.
Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.. „BMJ”. 344, s. d8190, 2012. DOI: 10.1136/bmj.d8190. PMID: 22240117. PMCID: PMC3257215.
Schlesinger N. Diagnosis of gout. „Minerva Med.”. 98 (6), s. 759–67, Grudzień 2007. PMID: 18299687.
Sachs L, Batra KL, Zimmermann B. Medical implications of hyperuricemia. „Med Health R I”. 92 (11), s. 353–55, Listopad 2009. PMID: 19999892.
Jordan DR, Belliveau MJ, Brownstein S, McEachren T, Kyrollos M. Medial canthal tophus. „Ophthal Plast Reconstr Surg”. 24 (5), s. 403–4, 2008. DOI: 10.1097/IOP.0b013e3181837a31. PMID: 18806664.
Sano K, Kohakura Y, Kimura K, Ozeki S. Atypical Triggering at the Wrist due to Intratendinous Infiltration of Tophaceous Gout. „Hand (N Y)”. 4 (1), s. 78–80, marzec 2009. DOI: 10.1007/s11552-008-9120-4. PMID: 18780009. PMCID: PMC2654956.
Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. „Arthritis Rheum.”. 57 (5), s. 816–21, Czerwiec 2007. DOI: 10.1002/art.22762. PMID: 17530681.
Abrams B. Gout is an indicator of sleep apnea. „Sleep”. 28 (2), s. 275, Luty 2005. PMID: 16171252.
Zhang W, Doherty M, Bardin T. i wsp.. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). „Ann. Rheum. Dis.”. 65 (10), s. 1312–24, Październik 2006. DOI: 10.1136/ard.2006.055269. PMID: 16707532. PMCID: PMC1798308.
Winzenberg T, Buchbinder R. Cochrane Musculoskeletal Group review: acute gout. Steroids or NSAIDs? Let this overview from the Cochrane Group help you decide what's best for your patient. „J Fam Pract”. 58 (7), s. E1–4, lipiec 2009. PMID: 19607767.
Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. „Annals of Emergency Medicine”. 49 (5), s. 670–7, 2007. DOI: 10.1016/j.annemergmed.2006.11.014. PMID: 17276548.
JS Sundy, Baraf, HS, Yood, RA, Edwards, NL, Gutierrez-Urena, SR, Treadwell, EL, Vázquez-Mellado, J, White, WB, Lipsky, PE, Horowitz, Z, Huang, W, Maroli, AN, Waltrip RW, 2nd, Hamburger, SA, Becker, MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.. „JAMA: the Journal of the American Medical Association”. 306 (7), s. 711–20, 17.08.2011. DOI: 10.1001/jama.2011.1169. PMID: 21846852.
S Ali, Lally, EV. Treatment failure gout.. „Medicine and health, Rhode Island”. 92 (11), s. 369-71, listopad 2009. PMID: 19999896.
Kim SY, De Vera MA, Choi HK. Gout and mortality. „Clin. Exp. Rheumatol.”. 26 (5 Suppl 51), s. S115–9, 2008. PMID: 19026153.
rozdział 87: Gout and Hyperuricemia. W: William N Kelley: KELLEY'S Textbook of Rheumatology. Wyd. 8th. Elsevier, 2008. ISBN 978-1-4160-4842-8. OCLC495275308. Brak numerów stron w książce
NaomiN.SchlesingerNaomiN. i inni, Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions, „Annals of the Rheumatic Diseases”, 71 (11), 2012, s. 1839–1848, DOI: 10.1136/annrheumdis-2011-200908, ISSN0003-4967.
